RE:DY
You sound like a traumatized victim of some sort of shareholder abuse who is resigned to ultimate failure. Were you here in a previous IR capacity? That is unfortunate. I think that there are several catalysts on the near term horizon. But You may be right. The stock is fairly valued for a marketing submission stage biotech and it shouldn't move until a decison from the FDA is rendered, as is the case with all biotechs at this mature stage. Yes that plant that no analyst in North America is going to care about is a tremendous burden and greatly overshadows the BLA submission itself. I know that the Seeking Alpha author was very leary of the plant as well. I apologize for my insensitive stupidity.